Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
作者信息
Basalay Maryna V, Davidson Sean M, Yellon Derek M
机构信息
The Hatter Cardiovascular Institute, University College London, London, UK.
出版信息
Neural Regen Res. 2020 Oct;15(10):1852-1853. doi: 10.4103/1673-5374.280313.
Abstract
摘要
相似文献
1
Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
Neural Regen Res. 2020 Oct;15(10):1852-1853. doi: 10.4103/1673-5374.280313.
2
Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Diabetologia. 1998 Mar;41(3):271-8. doi: 10.1007/s001250050903.
3
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Biol Chem. 2003 Dec;384(12):1543-51. doi: 10.1515/BC.2003.171.
4
Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Mol Neurobiol. 2018 Apr;55(4):3007-3020. doi: 10.1007/s12035-017-0550-2. Epub 2017 Apr 29.
5
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
J Mol Endocrinol. 2003 Dec;31(3):529-40. doi: 10.1677/jme.0.0310529.
6
Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Biochemistry. 2001 Mar 6;40(9):2860-9. doi: 10.1021/bi0014498.
7
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.
J Med Chem. 2017 Sep 14;60(17):7434-7446. doi: 10.1021/acs.jmedchem.7b00787. Epub 2017 Aug 16.
8
Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
Pharmacol Res. 2015 Dec;102:276-85. doi: 10.1016/j.phrs.2015.10.008. Epub 2015 Nov 3.
9
Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
Eur J Clin Invest. 1999 Jul;29(7):610-4. doi: 10.1046/j.1365-2362.1999.00440.x.
10
Biological activity of GLP-1-analogues with N-terminal modifications.
Regul Pept. 1999 Feb 5;79(2-3):93-102. doi: 10.1016/s0167-0115(98)00155-4.
引用本文的文献
1
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.
Cardiovasc Diabetol. 2022 Nov 15;21(1):242. doi: 10.1186/s12933-022-01686-3.
2
Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways.
Neurochem Res. 2022 Jul;47(7):1904-1916. doi: 10.1007/s11064-022-03574-4. Epub 2022 Mar 29.
3
(D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer's disease transgenic mice.
Neural Regen Res. 2022 Sep;17(9):2072-2078. doi: 10.4103/1673-5374.335168.
4
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
Br J Pharmacol. 2022 Feb;179(4):659-676. doi: 10.1111/bph.15462. Epub 2021 May 6.
本文引用的文献
1
Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.
Cardiovasc Drugs Ther. 2019 Dec;33(6):661-667. doi: 10.1007/s10557-019-06915-8.
2
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14.
3
The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection-evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology.
Basic Res Cardiol. 2018 Oct 11;113(6):43. doi: 10.1007/s00395-018-0704-z.
4
Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
Diab Vasc Dis Res. 2018 Nov;15(6):567-570. doi: 10.1177/1479164118788079. Epub 2018 Jul 19.
5
Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies.
Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):559-569. doi: 10.1111/bcpt.12974. Epub 2018 Mar 15.
6
Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.
Ann Med. 2017 Nov;49(7):552-561. doi: 10.1080/07853890.2017.1306653. Epub 2017 Mar 31.
7
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.
Cardiovasc Res. 2016 Dec;112(3):669-676. doi: 10.1093/cvr/cvw216. Epub 2016 Oct 4.
8
The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia.
J Neuroinflammation. 2016 Aug 26;13(1):204. doi: 10.1186/s12974-016-0661-0.
9
Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
Int J Cardiol. 2016 Apr 1;208:109-14. doi: 10.1016/j.ijcard.2015.12.009. Epub 2015 Dec 15.
10
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
J Endocrinol. 2014 Mar 7;221(1):T31-41. doi: 10.1530/JOE-13-0221. Print 2014 Apr.
Zotero 插件